Indiana’s Drug-Testing Employer Base

Last verified: April 2026

The Big Pharma + Big Auto + Big Steel Concentration

Indiana’s major employers are unusually concentrated in industries with strict pre-employment and random drug testing:

Pharma & Healthcare

• Eli Lilly (Indianapolis HQ) — ~10,500 Indiana employees, FDA-regulated; pre-employment + reasonable suspicion testing standard
• Roche Diagnostics (Indianapolis)
• IU Health, Community Health, Ascension St. Vincent, Parkview Health, Lutheran Health Network — major hospital systems with mandatory testing for clinical roles

Big Auto Manufacturing

• Subaru of Indiana Automotive (SIA) — Lafayette, ~6,000 employees, Japanese-corporate strict testing posture
• Toyota Motor Manufacturing Indiana (TMMI) — Princeton, ~7,500 employees, Japanese-corporate strict
• Honda Manufacturing of Indiana (HMIN) — Greensburg, ~2,800 employees
• General Motors Fort Wayne Assembly — Roanoke, ~4,400 employees
• Stellantis Kokomo Transmission Plant — ~7,000 employees
• Cummins (Columbus HQ) — engines, FMCSA/DOT testing for many roles

Steel & Heavy Industry

• U.S. Steel Gary Works — Gary, ~3,800 employees
• ArcelorMittal (now Cleveland-Cliffs) Indiana Harbor — East Chicago, ~3,500 employees
• NIPSCO (Northern Indiana Public Service) — utility

Logistics & Transportation

• FedEx (Indianapolis IND superhub)
• UPS — Indianapolis distribution
• Major trucking corridors — Indianapolis is “the Crossroads of America”; FMCSA per se rules apply to all CDL holders

Federal DOT/FMCSA testing under 49 CFR Part 40 sets marijuana metabolite cutoffs at 50 ng/mL initial and 15 ng/mL confirmation. CDL drivers, transit workers, pipeline workers, and pilots are subject to mandatory testing — and DOT does not recognize state medical cannabis programs as a valid medical use.

49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs

The Per Se Metabolite DUI Trap

Indiana’s workplace drug-testing posture combines with the state’s per se zero-tolerance metabolite DUI rule under IC 9-30-5 to create a uniquely punitive enforcement regime. THC metabolites can persist 30+ days after use; an employee who legally consumes cannabis in Michigan on a Saturday and is randomly drug-tested on a Wednesday at work in Indiana faces both employer discipline and potential DUI exposure if pulled over driving home that same evening.

P.L. 142-2020 and P.L. 49-2021 added a limited marijuana-metabolite affirmative defense to the per se DUI statute — but this protects only against criminal DUI charges, not against employer adverse action. Indiana has no statutory employment protection for off-duty cannabis use, even in border states. See DUI & driving.

Federal Workplace Layer

Federal employers and federal contractors operate under the Drug-Free Workplace Act of 1988 (41 U.S.C. §81) and SAMHSA’s 5-panel federal drug test, which includes THC. Security clearance positions are governed by SF-86 question 23: any cannabis use must be disclosed; current use is disqualifying; state medical-card status provides no defense (Indiana doesn’t have one anyway). ATF Form 4473 question 21.g requires denial of firearm purchase to any “unlawful user” of marijuana. See federal & military.

What Employers Look For

• Pre-employment — standard for nearly all major Indiana employers
• Random — common in safety-sensitive roles (trucking, manufacturing, healthcare)
• Reasonable suspicion — based on supervisor observation
• Post-accident — mandatory for OSHA-recordable incidents
• Return-to-duty — after a positive test or rehabilitation
• Follow-up — periodic testing during a recovery program

Cannabis is the most commonly detected drug in Indiana workplace testing — ~60% of positive results in 2024 industry data. The persistence of THC metabolites in fat tissue (urinary detection up to 30 days for chronic users) makes cannabis uniquely vulnerable to detection compared with shorter-window substances.

Explore Drug Testing